We are delighted that CMS recognizes the therapeutic value of proton therapy.

AMS pleased with CMS’ upsurge in 2012 payment price for proton therapy AMERICAN SHARED HOSPITAL Solutions , a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, said today that the recent announcement by the Centers for Medicare & Medicade Solutions of a 15 percent increase in the payment price of proton therapy for hospital based centers beginning in 2012 strengthens the economic case for the proton centers now under development by the Company. ‘We are delighted that CMS recognizes the therapeutic value of proton therapy, right now widely regarded as the perfect radiation treatment for a growing variety of cancers. This payment boost will facilitate the advancement of much-required proton therapy centers through the entire national country, ‘ said AMS Chairman and CEO Ernest A erectile dysfunction treatment .

The Stage I/II clinical study is scheduled to begin before 2013. ‘This partnership leverage’s AMT’s proven knowledge in cGMP manufacturing of gene therapy products and our experience in progressing the products through clinical advancement and the regulatory processes needed for successful commercialization,’ stated Jorn Aldag, CEO of AMT. ‘In addition, we will have a choice to acquire full commercial rights for this program on completion of the Phase I/II study, which facilitates our strategy to build a pipeline of orphan and ultra-orphan indications. ‘ Related StoriesStudy suggests potential fresh method to block cancer-leading to geneSingle gene variation may impact obesity in children, adultsMU researchers treat dogs with DMD, plan for human medical trialsMuriel Eliaszewicz, Medical Director of Institut Pasteur, stated: ‘AMT is among the only businesses in the world which has a proven ability in manufacturing cGMP quality gene therapy products, not only in batches sufficient for medical development but in support of a potential regulatory approval also.